-

Market Failure? kENUP and YUVEDO High-Level Online Event Kick-starts Call for Projects Tackling the Growing Threat of Parkinson’s and Other Neurodegenerative Diseases.

BERLIN--(BUSINESS WIRE)--On Friday, 18 September 2020, YUVEDO Foundation and kENUP Foundation held a high-level online conference to kick-start an open public call for projects tackling the growing threat of Parkinson’s (PD) and other neurodegenerative diseases (NDD). Despite the predictable medical, social and economic challenges of NDDs, too little has happened in recent years to address the underlying causes of NDDs.

An expert report by Professor Maier-Rigaud of NERA Economic Consulting presented at the conference, showed that there are indications for market and regulatory failure around the development of interventions against PD and other NDDs: High risk in product development is associated with massive cost but little potential profit. This has meant that many pharmaceutical companies have stopped their R&D investment in drugs or biologicals for the prevention and treatment of NDDs.

‘Project Brainstorm aims at developing a financing mechanism setting the right incentives to eliminate underlying market failures’ says Jörg Karenfort, Co-Founder of YUVEDO Foundation and partner at DENTONS.

‘Project Brainstorm developed by patients with broad support from leading researchers constitutes a timely response to the potential market failures underlying the development of interventions against neurodegenerative diseases. I support the need for further empirical research into these issues, ideally combined with a blueprint project such as the innovative Brainstorm Fund project’ said Katarina Barley, Vice-President of the European Parliament.

Holm Keller, Executive Chairman of kENUP Foundation said: ‘Brainstorm aims at reviving the fight against NDDs by initiating a new innovative financing mechanism providing venture loans at preferential terms to incorporated, scientifically promising projects not yet pursued by the pharmaceutical industry. This will help extend the deal-flow in the domain of NDDs.’

‘In order to jumpstart and accelerate the fight against diseases like Parkinson’s and Alzheimer’s I call on everyone to contribute to Project Brainstorm. YUVEDO Foundation is addressing an important public health issue that needs to be solved sooner than later’, added Elmar Brok, former Member and Committee Chair of the European Parliament.

Brainstorm is currently scouting relevant scientific and commercial communities for projects that develop interventions against neurodegenerative diseases and could contribute to the success of the portfolio. Companies interested in working with Brainstorm should contact Brainstorm at www.brainstormfund.org.

Contacts

Tobias Mac-Lean
maclean@kenup.eu

kENUP

Details
Headquarters: Kalkara, Republic of Malta
CEO: Holm Keller
Employees: 15
Organization: NON


Contacts

Tobias Mac-Lean
maclean@kenup.eu

Social Media Profiles
More News From kENUP

Barbados’ Prime Minister Mia Amor Mottley Announces Transatlantic Bridge Between the Caribbean, Latin America and Africa to Develop and Manufacture Pharmaceuticals for Global Public Health

SHARM EL-SHEIKH, Egypt--(BUSINESS WIRE)--Today, Prime Minister of Barbados Mia Amor Mottley, President of the Co-operative Republic of Guyana H.E. Mohamed Irfaan Ali, and President of the Republic of Rwanda. H.E. Paul Kagame met in Sharm El-Sheikh on the sidelines of COP 27 to discuss the furthering of pharmaceutical equity for global public health with President of the European Commission Ursula von der Leyen, and Director-General of the World Health Organization (WHO) Dr Tedros Adhanom Ghebre...

Announcement at kENUP Roundtable: BioNTech Plans mRNA Facility in Africa in Mid-2022

KIGALI, Rwanda--(BUSINESS WIRE)--BioNTech SE today announced that the Company plans to initiate the construction of the first state-of-the-art manufacturing site for mRNA-based vaccines in the African Union in mid-2022. This is the next step in BioNTech’s efforts to implement sustainable end-to-end vaccine supply solutions on the African continent. The decision is the result of a meeting between Rwanda’s Minister of Health, Dr Daniel M. Ngamije, Senegal’s Minister of Foreign Affairs Aïssata Tal...

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention

KIGALI, Rwanda--(BUSINESS WIRE)--Today, at a side meeting during the AU-EU Ministerial Summit in Kigali, Rwanda, Prof Salim Abdool Karim, Director of CAPRISA, announced a collaboration with a leading life science company Evotec for the designing and development of CAP256, a broadly neutralizing antibody against HIV. The project is a major expansion of the development of an antibody originally developed jointly by CAPRISA and the Vaccine Research Center (VRC) of the National Institute of Allergy...
Back to Newsroom